Bayer’s eight-year Roundup nightmare may finally have an expiration date — and the market can’t decide if it’s relieved or terrified.
On Tuesday, Bayer’s Monsanto unit filed a proposed $7.25 billion class-action settlement in Missouri state court designed to resolve roughly 65,000 pending lawsuits and cap future claims over a 21-year period. The lawsuits allege that Roundup, the world’s most widely used weedkiller, causes non-Hodgkin lymphoma and other cancers. Bayer denies wrongdoing and maintains decades of studies show the product is safe. But the company has already paid about $10 billion to settle previous Roundup cases since 2020, and a $2.1 billion Georgia jury verdict in March shattered any illusion that the worst was behind them.
Shares initially surged as much as 7.7% on the news, hitting their highest level since September 2023. Deka Investment’s Ingo Speich called the move welcome, saying it “significantly reduces the legal risks” because it covers future claims — something Bayer’s failed 2020 settlement attempt didn’t accomplish. Individual payouts could reach $198,000 or more, determined by a tiered system based on exposure level, age at diagnosis, and cancer type.
But the math isn’t exactly pretty. Bayer expects its litigation provisions and liabilities to balloon from €7.8 billion to €11.8 billion. The company anticipates roughly €5 billion in litigation-related payouts in 2026 alone, and is now guiding for negative free cash flow for the full year. That’s on top of the $10 billion already spent. For a company that paid $63 billion for Monsanto in 2018, the total legal bill is approaching a third of the acquisition price — a staggering reminder that the cheapest acquisition is sometimes the one you don’t make.
The real wild card is the U.S. Supreme Court. In January, the court agreed to hear Bayer’s appeal arguing that federal EPA labeling requirements should block state-level failure-to-warn lawsuits — oral arguments are scheduled for late April. A favorable ruling could dramatically limit Bayer’s exposure going forward, essentially pulling the legal rug out from under future plaintiffs. Union Investment’s Markus Manns cautioned that Tuesday’s settlement “buys Bayer time, but without a win in the Supreme Court, a new wave of lawsuits could roll over Bayer in a few years.”
For investors willing to stomach the risk, this is one of the more interesting asymmetric setups in the market right now. Bayer’s stock has been obliterated since the Monsanto deal — down roughly 70% from its 2018 highs. If the Supreme Court rules favorably in April and this settlement gets judicial approval, the company could see a genuine re-rating as the Roundup cloud lifts. If either goes wrong, though, the bleeding continues. It’s the kind of situation where the outcome is binary and the odds are genuinely uncertain — which is exactly when stocks get mispriced.